Compare ARXS & GH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARXS | GH |
|---|---|---|
| Founded | N/A | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Medical Specialities |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1B | 20.6B |
| IPO Year | 2026 | 2018 |
| Metric | ARXS | GH |
|---|---|---|
| Price | $58.40 | $160.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 19 |
| Target Price | N/A | ★ $119.79 |
| AVG Volume (30 Days) | 787.7K | ★ 2.2M |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.74 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $982,021,000.00 |
| Revenue This Year | N/A | $33.30 |
| Revenue Next Year | N/A | $28.27 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 32.88 |
| 52 Week Low | $38.69 | $43.66 |
| 52 Week High | $58.39 | $176.58 |
| Indicator | ARXS | GH |
|---|---|---|
| Relative Strength Index (RSI) | 72.31 | 58.88 |
| Support Level | $40.79 | $152.64 |
| Resistance Level | N/A | $174.08 |
| Average True Range (ATR) | 3.25 | 8.19 |
| MACD | 1.65 | -0.21 |
| Stochastic Oscillator | 90.96 | 51.65 |
Arxis Inc designs and manufactures proprietary electronic and mechanical components used in applications that require performance in extreme environments. The company operates in two reportable segments: i) Electronic Components: It provides specialized, engineered electronic components and interconnect solutions, including connectors, cable assemblies, microelectronic packaging, RF and microwave products, power products, sensors, capacitors and resistors. and ii) Mechanical Components: It provides precision and self-lubricating bearings, seals, springs, gaskets and ducting, and radar absorbing materials. The majority of the company's revenue is derived from the Mechanical Components segment. Geographically, it generates the maximum revenue from the United States.
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tumors, Reveal for molecular residual disease testing, and Shield for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.